

# Yesim Eralp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2204655/publications.pdf>

Version: 2024-02-01

26  
papers

391  
citations

840585

11  
h-index

794469

19  
g-index

26  
all docs

26  
docs citations

26  
times ranked

534  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anemia in Oncology Practice. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 371-379.	0.6	88
2	Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer. Lymphatic Research and Biology, 2018, 16, 28-35.	0.5	33
3	Stevens-Johnson Syndrome in a Patient Receiving Anticonvulsant Therapy During Cranial Irradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 347-350.	0.6	29
4	Prognostic Factors and Survival in Late Adolescent and Adult Patients With Small Round Cell Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 418-424.	0.6	27
5	Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy. Oncology Letters, 2014, 8, 845-848.	0.8	24
6	Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecologic Oncology, 2008, 108, 248-250.	0.6	23
7	Malignant Ovarian Germ Cell Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 191-196.	0.6	22
8	Resectable Thymoma: Treatment Outcome and Prognostic Factors in the Late Adolescent and Adult Age Group. Cancer Investigation, 2003, 21, 737-743.	0.6	20
9	Prognostic Factors in Localized Aggressive Non-Hodgkinâ€™s Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 1-5.	0.6	18
10	Oral Etoposide (VP16) in Platinum-Resistant Epithelial Ovarian Cancer (EOC). American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 358-362.	0.6	18
11	Prognostic Factors in Localized Soft-Tissue Sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 411-415.	0.6	14
12	TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer. BMC Cancer, 2021, 21, 357.	1.1	14
13	Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2Î± Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 215-223.	0.6	11
14	Thymidine Labeling Index: Prognostic Role in Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 400-406.	0.6	9
15	Treatment of Aggressive Non-Hodgkinâ€™s Lymphoma With Dose-Intensified Epirubicin in Combination of Cyclophosphamide, Vincristine, and Prednisone (CEOP-100). American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 570-575.	0.6	8
16	True Local Recurrences after Breast Conserving Surgery have Poor Prognosis in Patients with Early Breast Cancer. Cureus, 2016, 8, e541.	0.2	7
17	Possible role of stress, coping strategies, and life style in the development of breast cancer. International Journal of Psychiatry in Medicine, 2018, 53, 207-220.	0.8	7
18	Roles of Biopsychosocial Factors in the Development of Breast Cancer. The Journal of Breast Health, 2017, 13, 206-212.	0.4	7

#	ARTICLE	IF	CITATIONS
19	The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience. The Journal of Breast Health, 2014, 10, 209-215.	0.4	5
20	Aggressive Non-Hodgkinâ€™s Lymphoma Treated at the Institute of Oncology, Istanbul. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 502-508.	0.6	2
21	The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus. Translational Oncogenomics, 2016, Suppl. 1, 1-7.	1.7	2
22	Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial. Balkan Medical Journal, 2020, 37, 104-107.	0.3	2
23	Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center. Turkish Journal of Thoracic and Cardiovascular Surgery, 2021, 29, 487-495.	0.2	1
24	Preoperative Therapy for Operable Breast Cancer. , 2016, , 251-263.		0
25	Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.. Journal of Clinical Oncology, 2020, 38, e13646-e13646.	0.8	0
26	Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.. Journal of Clinical Oncology, 2020, 38, e13055-e13055.	0.8	0